Rocket Lab Corp (NASDAQ: RKLB) shares fell sharply on 18 September 2026, days after the launch company completed a $1.94bn equity raise to fund its acquisition of Iridium Communications.
The stock closed at $64.57, down 4.79% on the day, according to CNN Markets, having ended the previous session at $67.82. GuruFocus put the decline at roughly 5%, tying it to investor concern over dilution from the offering.
The mechanics of the Rocket Lab equity raise
Rocket Lab sold about 29.3 million shares through an at-the-market programme, raising $1.944bn, according to figures reported by GuruFocus and confirmed in an exhibit filed with the SEC. The offering was completed on 15 September 2026.
The proceeds are earmarked to finance Rocket Lab’s pending takeover of Iridium Communications. Alongside the equity raise, Iridium amended its credit facility to add $1.775bn of term loans, while Rocket Lab terminated a $3.6bn bridge loan commitment it no longer needed once the ATM funding was in place, according to reporting by Yahoo Finance.
That sequencing matters to shareholders. Financing an acquisition through fresh stock rather than debt avoids interest costs but spreads existing holders’ claims on the business more thinly – precisely the trade-off investors appeared to be pricing in on Friday.
A slide that predates the raise
Friday’s drop did not happen in isolation. Rocket Lab shares had already fallen roughly 39% between mid-June and 10 September 2026, according to analysis published by Trefis via Yahoo Finance, well before the equity raise was announced.
The Friday tumble also coincided with a broader pullback across space-sector stocks, including AST SpaceMobile and Planet Labs, which one outlet attributed to sector rotation rather than company-specific news, according to Pluang News. That leaves the dilution narrative as a contributing factor rather than the sole explanation for the move.
Trading volume on the day ran at 1.93 times the stock’s 20-day average, with shares changing hands within a 20-day range of $60.67 to $69.26 – a pattern consistent with a market digesting a large, fresh supply of stock.
Backlog offers a counterpoint
Rocket Lab’s finances tell a more mixed story than the share price alone suggests. The company’s order backlog stood at $2.36bn around the same period, a figure highlighted by The Motley Fool as a counterweight to recent price weakness.
Revenue has climbed steadily through Rocket Lab’s most recent quarters, reaching $234.1m in the three months to 30 June 2026, up from $92.8m in the first quarter of 2024, according to filings with the SEC. The company remains loss-making: it reported a net loss of $49.3m for the second quarter of 2026, narrower than the $66.4m loss booked a year earlier.
The macro backdrop offered little explanation for the sector-wide wobble. The 10-year Treasury yield stood at 4.94% on 17 September, down slightly from a prior reading of 5.01%, with the 2-year yield at 4.67%, according to FRED data from the Federal Reserve Bank of St. Louis – a modestly easing rate environment rather than a driver of the selloff.
What investors are watching
The Iridium acquisition remains the central swing factor for Rocket Lab’s near-term valuation. Investors are likely to watch how quickly the enlarged share count translates into earnings contribution from the combined business, and whether the backlog growth cited by analysts converts into revenue at a pace that outstrips the dilution from September’s raise.
For now, the equity raise has done its job of funding the deal without new debt. Whether the market comes to see that as prudent balance-sheet management or simply more shares chasing the same growth story is likely to depend on how Rocket Lab’s next quarterly results, due in the coming months, frame the Iridium integration.
This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
